Clinical study of vaccine for Parkinson’s disease starts

Thursday 7 June 2012

Affiris AG has started a Phase 1 study of a new vaccine for Parkinson’s disease which it says is aimed at modifying the disease rather than treating symptoms. The programme has received financial support from the Michael J Fox Foundation.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Austria